How semaglutide affects lean mass percentage during weight loss

The myth: semaglutide burns muscle as readily as fat

This is the version of the story that circulates on forums, and it deserves a direct answer: the evidence does not support it. What the STEP 1 trial (68 weeks, semaglutide 2.4mg against placebo, published in the New England Journal of Medicine) showed is that the majority of weight lost was fat mass. A significant minority was lean mass, as happens with almost any form of sustained caloric deficit. That is not unique to semaglutide, and it is not a reason to avoid effective treatment. The more useful question is how big that lean-mass fraction was, why it varies, and what you can do to shift the ratio in your favour.

In most semaglutide body-composition sub-studies, somewhere between 15% and 30% of lost weight was lean tissue, with fat mass accounting for the rest, and our Redefine 1 trial page sets out the semaglutide weight loss percentages from that programme in full. The range is wide because the studies used different measurement methods (DEXA, bioelectrical impedance), enrolled different populations, and ran for different durations. Participants who exercised regularly and hit reasonable protein targets consistently sat toward the lower end of that range, less lean-mass loss, more fat-mass loss. That pattern is reproducible enough to form the basis of clinical guidance, even if no single trial pins it to a single percentage.

One practical check you can do in under a minute: stand on a body-composition scale (or note the readings if your GP uses one) and record fat mass and lean mass separately, not just total weight. Tracking both across months gives you a far cleaner picture of whether treatment is doing what it should than total weight alone.

Why lean mass percentage often improves even when lean mass falls slightly

This is the part of the story that gets lost. Suppose someone starts treatment at 110 kg with 60 kg of lean mass and 50 kg of fat mass. Their lean mass percentage is 54.5%. After 68 weeks they weigh 93 kg, they have lost 17 kg, of which 13 kg was fat and 4 kg was lean mass. Their lean mass is now 56 kg. The percentage? Just over 60%. Despite losing some absolute lean tissue, the proportion of their body that is lean has gone up by around six percentage points, because fat loss was three times larger. You can read more about how these numbers play out across the STEP programme on our STEP 1 trial results page.

This is not a reason to be complacent about lean-mass preservation, losing 4 kg of muscle is still a real cost, particularly for older adults or anyone with a physically demanding job. But it does explain why many people feel stronger and more mobile after treatment even though their total lean mass has declined. The NHS encourages people taking weight-management injections to increase physical activity alongside treatment, specifically because it modifies this composition split. That guidance is practical and worth taking seriously, not just ticking a box.

What drives lean mass loss, and what protects against it

Lean-mass loss during caloric deficit follows predictable biology. The larger the deficit, the faster the loss, and the less protein available from diet, the more the body draws on muscle. Semaglutide reduces appetite substantially, which means some people unintentionally drop protein intake alongside overall calories. A daily target in the range of 1.2–1.6 g of protein per kilogram of body weight is commonly cited in obesity-medicine literature as protective during significant weight loss, though the right figure for you is a conversation for your prescriber or a registered dietitian, not a general article.

Resistance training (two or three sessions a week of progressive load-bearing exercise) is the other lever with consistent evidence behind it. It does not eliminate lean-mass loss, but it meaningfully reduces it. Our page on semaglutide and body composition goes into the mechanisms in more detail. The NHS notes this in its guidance on weight-management injections, and it sits at the heart of the "wraparound care" model that accompanies both NHS and private treatment. Treatment does not work in isolation; the lifestyle element is doing real work.

It is also worth knowing that semaglutide's effect on inflammation may indirectly help muscle health. Some research has tracked markers such as hsCRP during treatment, suggesting systemic inflammation falls alongside body weight, you can read about that on our semaglutide and hsCRP page. Chronic low-grade inflammation is itself a driver of muscle breakdown, so reducing it may partially offset some of the lean-mass loss you would otherwise expect from a caloric deficit alone. The evidence here is early-stage and should not be overstated, but it is a reasonable part of the picture.

How this applies if you are considering semaglutide treatment

Body composition goals are a legitimate part of discussing treatment with a prescriber. If preserving muscle is a priority for you (because you train regularly, because you are over 60, or because you have a physically demanding life) that context belongs in your consultation. A prescriber who understands your starting point can factor it into the clinical discussion and, where appropriate, refer you to a dietitian.

Semaglutide for weight management is licensed in the UK as Wegovy; you can find a full overview on our Wegovy information page, and a breakdown of the typical weight-loss percentages people see over treatment on our Wegovy percentage weight loss page. The NICE recommendation for semaglutide, published under TA875, sets out the eligibility criteria that apply when treatment is accessed through the NHS. Private treatment through a regulated pharmacy follows the licensed criteria in the product's SmPC, which your prescriber will apply to your individual case.

If you have read enough to want a clinical conversation, the next step is straightforward. Check your eligibility with our prescribers, the consultation is free, reviewed the same working day by a GPhC-registered Independent Prescriber, and comes with no obligation.